Furthermore, administration of TLR7-agonist influencing the folate receptor β-positive TME cells reduced their immunosuppressive function, increased CD8+ T cell infiltration, enhanced M1/M2 macrophage ratio, and prompted other profitable anti-tumor responses causing improvement of patients’ overall survival [177]. This evidence concerns the gene CD8A and neoplasm.